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Introduction
The toxicity of 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD), a contaminant formed
during the manufacture of the herbicide
2,4,5-trichlorophenoxyacetic acid (2,4,5-T)
is well known (1-4). The widespread utiliza-
tion of this compound has caused increased
concern about the potential health hazards
created by the presence of TCDD in the en-
vironment. The articles which accompany
this account, indeed, attest to the highly
toxic nature of TCDD in both laboratory
animals and man.
Interest in TCDD as a potential porphyro-
genic agent arose when porphyria cutanea
tarda, a form of hepatic porphyria, occurred
in industrial workers associated with the
manufacture of 2,4,5-T (5). Hepatic porphy-
ria is a syndrome characterized by a variety
of symptoms including the overproduction
and excretion of porphyrins, pigmentation
of the skin, photosensitivity, and intestinal
and neurological disorders. The disease is
characterized biochemically by an increase
in the activity of the mitochondrial enzyme
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8-aminolevulinic acid (ALA) synthetase,
which is the first and rate-limiting enzyme
in the heme biosynthetic pathway (6) (Fig.
1). The possibility that TCDD has porphy-
rogenic properties has been indicated by the
recent observation that TCDD is a potent
inducer of hepatic ALA synthetase in chick
embryos (7). There is, however, no evidence
to indicate that TCDD produces similar ef-
fects in mammalian species. The chick em-
bryo system is exquisitely sensitive to the
effects of agents which induce ALA synthe-
tase (8). Previous studies from our labora-
tory (9, 10), on the other hand, have shown
that mammalian species demonstrate a
striking variability in their response to por-
phyric agents, especially at different stages
of development.
These studies were undertaken, therefore,
to determine the possible porphyrogenicity
of TCDD in mammalian species and to as-
sess further the utility of the chick embryo
liver system as an indicator of the potential
porphyrogenic effects of environmental
agents in mammals.
Materials and Methods
ALA synthetase activity was determined
by two procedures. In liver homogenates
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FIGURE 1. Heme biosynthetic pathway.
ALA synthetase activity was assayed using
the ion exchange chromatography technique
described by Mauzerall and Granick (11),
with liver homogenates prepared for incuba-
tion as described by Marver et al. (12).
ALA synthetase activity in subcellular frac-
tions and at various stages of enzyme puri-
fication was measured using the procedure
described by Scholnick et al. (13). In the
latter case the incubation medium was modi-
fied to include 10-4M GTP in addition to
the prescribed substrates.
The method of Scholnick was also used for
the isolation and 50-fold purification of
ALA synthetase from porphyric rat liver.
Hepatic subcellular fractions were prepared
as described by Hayaski et al. (14). Protein
concentrations were assayed by the method
of Lowry et al. (15).
All test animals were treated orally with
a standard solution of TCDD (10 Ag/ml)
dissolved in a corn oil/acetone mixture (6:1)
24 hr prior to sacrifice unless otherwise in-
dicated. Two groups of control animals were
used in all in vivo experiments. The first
group received only the corn oil/acetone mix-
ture in an amount equivalent to that in
which TCDD was administered to test ani-
mals. The second group was treated subcu-
taneously with allylisopropylacetamide
(AIA) (400 mg/kg), which is a well known
and potent inducer of ALA synthetase in
mammals (12, 16).
TCDD was obtained from Dow Chemical
Company, Midland, Michigan. AIA was a
gift from Hoffmann-LaRoche, Nutley, New
Jersey. All animals and other chemicals
were obtained from standard sources.
Results and Discussion
Initial studies were designed to determine
the potential porphyrogenic effects in rats
of TCDD when administered in doses up to
25 jug/kg, the reported LD50 for this species
(17). Male rats were treated with a single
5 or 25 ug/kg dose of TCDD, and hepatic
ALA synthetase activity was assayed at pe-
riods up to 28 days thereafter. In animals
receiving a single dose of AIA, ALA syn-
thetase activity increased to approximately
seven times the control level after 24 hr
and returned to control levels by the third
day after treatment. On the other hand,
TCDD did not significantly alter ALA syn-
thetase activity, as measured in whole liver
homogenates, during any part of the test
period in any of the animals. All measure-
ments of enzyme activity were within the
range observed in controls.
It has been recently determined (14) that
ALA synthetase is a mitochondrial enzyme
but is synthesized extramitochondrially on
the cytoplasmic ribosomes. The enzyme is
subsequently incorporated into the mito-
chondria, where it becomes active. ALA
synthetase activity may be altered by agents
which interfer with any aspect of this pro-
cess. It was, therefore, of interest to deter-
mine if TCDD might influence the subcellu-
lar localization of ALA synthetase and
thereby alter the regulation of hepatic hem-
Environmental Health Perspectives 222Table 1. Subcellular distribution of hepatic ALA synthetase in normal and
AIA- and TCDD-treated rats.a
ALA, nmole/mg protein-hr ± S.E.
Group Treatment Mitochondrial 9,00Og 105,000g Microsomal
fraction supernatant supernatant fraction
1 Corn Oil 0.52 ± 0.09 0.27 ± 0.08 0.24 ± 0.10 0.03 ± 0.01
2 AIA 2.26 ± 0.80 1.44 ± 0.40 1.47 ± 0.30 0.28 ± 0.10
3 TCDD 0.58 ± 0.10 0.34 ± 0.06 0.15 ± 0.43 0.01 ± 0.01
4 AIA + TCDD 2.91 ± 0.87 1.37 ± 0.51 1.17 ± 0.51 0.27 ± 0.08
aRats were treated with TCDD (25 ,Ag/kg) and/orAIA (400 mg/kg) 24 hr prior to sacrifice.
atopoiesis in a manner which could not be
detected when ALA synthetase activity was
measured in whole liver homogenates. The
results of these experiments are seen in Ta-
ble 1. Analysis of the subcellular distribu-
tion of ALA synthetase in adult rat liver
reveals a 2:1 distribution of activity between
mitochondrial and postmitochondrial frac-
tions. Most of the postmitochondrial activity
is retained in the 105,000g supernatant
fraction with very little found in the micro-
somes. Control rats in the group treated
with AIA showed substantial increases in
the ALA synthetase activity in all fractions
but relatively little alteration in the distri-
bution of activity between fractions after
24 hours. TCDD administered alone at 25
,ug/kg doses or together with AIA caused no
significant alteration of ALA synthetase
activity from that observed in control
groups. In addition, TCDD did not affect
the induction of ALA synthetase by AIA
nor alter the subcellular distribution of the
enzyme during induction. Similar observa-
tions were made when TCDD was adminis-
tered in 100 mg/kg doses or when these ex-
periments were conducted with female rats
or mice.
In vitro tests of the possible effects of
TCDD or ALA synthetase activity were
conducted in liver homogenates, isolated mi-
tochondria and on ALA synthetase purified
50-fold from porphyric rat liver. In enzyme
incubation mixtures containing TCDD in
concentrations ranging from 10-9 to 10-6M
no discernable effects on the enzyme activity
could be observed.
Finally, the potential porphyrogenic ef-
fects of TCDD during the perinatal period
were investigated. These studies were con-
ducted in fetal rats which were 3 days from
delivery, (-3 day), and on two groups of
newborn rats, 4 and 12 days after delivery
on the day of sacrifice. Newborn rats were
treated orally with 25 pg/kg doses of TCDD,
whereas fetal rats were treated by way of
the mother. Livers from mother rats served
as adult samples. The results are shown in
Table 2. In no case did ALA synthetase ac-
tivity in TCDD-treated rats differ from that
observed in untreated animals. Fetal ALA
synthetase is typically five to eight times
that of the adult (9) and declines to adult
levels shortly after birth. Refractoriness to
induction of ALA synthetase is observed un-
til the activity approaches that of the adult
(10, 18). At no stage of development, how-
ever, did the ALA synthetase activity in
TCDD-treated rats significantly differ from
that observed in controls.
These results are of particular interest in
view of the potent induction of ALA syn-
thetase activity produced by TCDD in the
chick embryos. The lack of a significant ef-
fect of TCDD on ALA synthetase in mam-
mals suggests that major differences exist
among these species in the biological mech-
anisms which determine the ultimate phar-
macological disposition of chemicals such of
TCDD. Species variations in drug distribu-
tion, biotransformation, and excretion are
well known (19). On the other hand, major
differences in the mode of action of TCDD
may also reflect alterations in the regulation
September 1973 223Table 2. Study of potential effects of TCDD on ALA synthetase during development in rats.a
ALA, nmole/hr-g liver ± S.E.
Group Treatment -3 day +4 day +12 day Adult
1 Corn oil 241 ± 31 94 ± 7 50 ± 16 45 ± 5
2 TCDD 253 ± 47 76 ± 21 60 ± 8 44 ± 13
3 AIA 248 ± 28 118 ± 12 113 ± 13 347 ± 17
a Pregnant and newborn rats were treated 24 hr prior to sacrifice with TCDD (25 ,ug/kg) or AIA (400
mg/kg).
of hepatic heme synthesis in these species.
Striking variations in the developmental
aspects of ALA synthetase regulation have
already been described. The chick embryo
liver is one of the most sensitive systems
available in which to study the induction of
ALA synthetase (8). In contrast, our previ-
ous studies (10) have shown that fetal
mammals are totally insensitive to the ef-
fects of drugs which induce or repress
hepatic ALA synthetase in chick embryo or
in adult animals. Moreover, fetal mamma-
lian ALA synthetase activity is significantly
elevated in comparison with that of the
adult (9), whereas the control level of ALA
synthetase in 17-day old chick embryo liver
is only one-third that measured in the adult
chicken (20).
Differences in porphyrin metabolism in
these two species is also suggested by the
failure of a wide variety of drugs which in-
duce hepatic porphyrin accumulation in
chick embryos to do so in mammalian liver
(21). Among the drugs capable of causing
significant increases in porphyrin levels in
chick embryo liver are 3,5-dicarbethoxy-1,4-
dihydrocollidine (DDC), glutethimide,
methsuximide, secobarbital, methylprylon,
and mephenytoin. Of this group, only DDC
is capable of producing porphyrin accumula-
tion in mice. In addition, it has been recently
indicated that uroporphyrinogen synthe-
tase, another enzyme in the heme biosyn-
thetic pathway, may play a rate-limiting
role in hepatic heme synthesis in certain
strains of mice (22).
It therefore appears that significant dif-
ferences exist among these species with re-
gard to various steps in the regulation of
hepatic heme synthesis and porphyrin meta-
bolism. These differences, along with varia-
tions in the capacity to metabolize and dis-
tribute drugs such as TCDD, may account
for the differences in susceptibility of these
species to the porphyrogenic effects of
TCDD and perhaps to other environmental
contaminants.
The foregoing considerations attest to the
increasingly prevalent observation that
many environmental agents are hazardous
not only by virtue of their inherent toxicity
but also because of their specificity of action
in different species. While utilization of non-
mammalian test systems may provide, in
some cases, a sensitive indication of the po-
tentially toxic effects of certain drugs and
chemicals in mammals, this study demon-
strates the necessity for developing test pro-
cedures which will more clearly predict
the deleterious effects of environmental con-
taminants in mammalian species, especially
in man.
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